Search This Blog

Monday, May 14, 2018

Up to 10% with ObamaCare coverage could jump to association health plans

  • new report from the Society of Actuaries found the proposed expansion of association health plans will provide lower-cost coverage options but will also cause result in higher premiums in the individual market.
  • Between 3% and 10% of those in Affordable Care Act marketplace plans will leave for AHPs if the Trump administration’s proposed rule is finalized. Those people are more likely to be young and healthy, so their absence will leave the marketplace plans with an unstable risk pool, according to the analysis published in The Actuary.
  • The report notes there is still uncertainty surrounding the proposal to expand AHPs, including “how many associations or issuers will form and market AHPs, and how other policy decisions, such as repeal of the ACA’s individual mandate penalty and the expansion of short-term limited duration insurance will affect the individual market.”

The Trump Administration wants to allow more small businesses, organizations and sole proprietors to band together and form AHPs. The thinking goes that AHPs will allow for greater bargaining power and lower healthcare costs for participants.
The proposed rule would allow small companies within a geographic area, even across state lines, to band together. An AHP would not be restricted to a “common interest,” such as operating in the same industry.
The proposal is one of the administration’s key planks, along with expanding short-term catastrophic health plans, to lower health plan costs and provide more choice.
AHPs could be an attractive alternative for young, healthy people who are paying more in the individual market to help offset the sicker members. “AHPs will likely be allowed to set premiums for policies that more accurately reflect the potential costs of older versus younger members, which should result in significant savings for younger individuals who move to AHPs,” according to the report.
The AHP proposal would let those plans avoid ACA regulations. For example, they wouldn’t have to offer coverage for the 10 essential health benefits required in the ACA, which includes maternity care and prescription drugs.
AHPs were once seen as a health insurance option for millions of people and small employers. However, AHPs dropped in popularity after the ACA instituted consumer protections. The plans were required to be treated the same as individual and small-group market plans, and thus had to cover people with pre-existing conditions. These regulations increased the cost to offer AHPs.
The Kaiser Family Foundation said only 6% of employers with fewer than 250 employees offered health insurance through AHPs in 2017.
With many questions about the AHP proposal still remaining, it’s tough to gauge exactly how the plans will affect the individual market. Factors that will influence the impact of AHPs include whether the final rule has a nondiscrimination provision, the specific criteria and standards for the plans, how much regulatory power states have and how associations and payers respond to the new rules.
The Actuary’s report looked at how AHPs will affect the self-employed population, which made up 10% of all workers in 2015.
The report doesn’t expect any impact on self-employed, low-income people who are eligible for subsidized ACA plans. However, among lower- to middle-class people (those between 250% and 400% of the federal poverty level), between 7% and 22% of the self-employed could move from an individual plan to an AHP.
People who aren’t eligible for any ACA subsidies are much more likely to leave the individual market. The report found between 24% and 78% of those people will move to an AHP.

Another Casualty of Pricey Healthcare: Credit Scores

After a devastating horse-riding accident in January 2017 landed him in the hospital for about 30 days, requiring trauma care and hospital-based therapy, Jeff Woodard considered himself lucky.
The bills amounted to hundreds of thousands of dollars. But Woodard’s employer-sponsored health insurance limited his out-of-pocket maximum payment to $5,000. He reached that “within like a day,” he recalled.
His retired parents relocated from their small town in Massachusetts to help Woodard, now 27, who lives just outside of Denver, through his recovery. With their support, and regular outpatient therapy, he returned to working full time in just two months.
But he didn’t expect another set of payments to haunt him and his parents for nearly a year, ultimately going to collections, and threatening to weaken his credit rating for years more.
While medical bills are a leading source of personal bankruptcy in the United States, a far more common problem is the widespread damage they do to people’s credit. Almost 40% of adults younger than 65 reported a lower credit score because of medical debt, according to the most recent Commonwealth Fund analysis, based on 2016 data.
That means greater difficulty with transactions such as financing mortgages, taking out student loans, or purchasing cars.
In Woodard’s case, his parents had been deliberate in making sure that all the care their son received was within his insurance network. But it turned out that the trauma doctors at the in-network hospital were not. They were employees of Aspen Medical Management, a Colorado Springs, Colo., physician staffing firm that employs physicians and contracts them out to hospitals.
That generated about $3,000 worth of out-of-network surprise bills, sent directly to Woodard. United Healthcare had paid Aspen the standard rate for in-network care, and Aspen expected Woodard to come up with the rest.
Stunned, Woodard complained to his insurer and Aspen, and filed paper appeals. His parents hectored Colorado lawmakers and filed complaints with both the hospital and various state agencies. But as notices from Aspen and then collections agencies piled up, with threats to report a delinquent bill to credit bureaus, his worry grew.
“I was planning on refinancing my mortgage,” he recalled, a change that he said would have saved him $15,000. “But if I got a bad hit to my credit score, it wouldn’t save me any money. I was paranoid about that.”
Woodard’s persistent appeals succeeded, and his debt was settled just days before it was set to hit his credit report.
“I was going to write [Aspen] a check, but my parents insisted I didn’t,” he said. “I was incredibly lucky — and it sucked.”
When contacted by Kaiser Health News, an Aspen spokeswoman said the company had no comment, declined to provide her full name and then hung up.
An Unpayable Bill, And Years-Long Damage
Even when patients like Woodard emerge with their credit unscathed after a medical crisis, the endless stream of collection letters and threats is a source of concern, often pressuring patients to pay medical bills they should not.
Medical debt isn’t like other financial obligations. It might result from unplanned illnesses and accidents, or because consumers do not fully understand the intricacies of a health plan. Good coverage is not necessarily sufficient to shield someone from considerable costs. It can take months of negotiation and processing for consumers to know what they actually owe.
Left unpaid, these bills are ultimately sent to collections agencies.
Eventually, that medical collection dings the patient’s credit, staying for as long as seven years, depending on state laws.
It’s part of a multibillion-dollar industry: In 2016, the most recent year for which there are figures, agencies collected just under 10% of the $792 billion consumers owed in overall debt, according to an industry report.
That same year, about 46.8% of collected debts were healthcare-related, according to data kept by the Consumer Financial Protection Bureau.
Any outstanding bills can have serious ramifications for consumers, explained Chi Chi Wu, a staff attorney at the Boston-based National Consumer Law Center, who specializes in medical debt and credit reporting.
“Let’s say, two years from now, mortgage rates plunge down to 2% and I want to refinance,” Wu said. “And the mortgage broker tells me, ‘You can’t get the best rate. Your credit score is 650 and it’s being dragged down from this unpaid collection from this hospital.'”
In that context, even an unmet deductible or copayment can be catastrophic.
Rodney Anderson, a mortgage broker in Plano, Texas, sees this regularly.
Starting in 2008, he noticed that almost half of his clients had weaker credit ratings — and therefore secured less favorable loans — because of medical debt. Even now, it affects “five to 10” of his clients each day.
The most recent federal analysis, a 2014 CFPB report, found that almost 20% of credit reports had at least one medical collection account listed. An average unpaid medical collection is about $580.
Protections that took effect in September 2017 could provide some relief.
As a result of a settlement reached by multiple state attorneys general and credit reporting agencies, collections agencies now must wait 180 days before reporting an unpaid medical bill to the credit bureaus to allow consumers adequate time to sort out insurance disputes.
A narrow provision of a banking regulation bill stalled in Congress would extend this waiting period to a full year for military veterans.
Apart from credit reporting modifications, some states, including Woodard’s Colorado, have laws on the books to protect patients from surprise billing, which many experts say trigger these financial issues. But these measures are also limited. They typically prohibit balance billing — charging patients for the difference between a list price and what insurance paid — in only certain care settings, or shield patients from the payment responsibility, though they don’t necessarily stop providers from sending a bill.
This patchwork approach reflects a larger truth: Efforts to legislate meaningful change have foundered.
Anderson, for instance, spent eight years and $2 million of his own money lobbying lawmakers in Washington to keep paid and settled medical debt off credit reports. He has since given up, after strong opposition from the credit reporting industry, which, Open Secrets data shows, consistently lobbied Congress about the legislation he supported.
Unpaid medical debt “is an important metric for lenders and creditors,” said Eric Ellman, senior vice president for public policy and legal affairs at the Consumer Data Industry Association, a major trade group. Citing changes such as the 180-day waiting period and upgrades to reporting systems, he added that “I’m not sure there’s more that needs to be done on this.”
Some observers argue, though, that changes in insurance design have made the issue more pressing.
Private insurance — both marketplace plans and those offered by employers — have shifted so consumers are responsible for more of their healthcare costs, noted Sara Collins, the Commonwealth Fund’s vice president for healthcare coverage and access. Middle-class people in particular, she added, are more likely to see unpayable medical bills, exposing them to the risk of medical debt.
January 2017 study found that 20% of patients who went from the ER to the hospital in 2014 likely received an unexpected medical bill. Meanwhile, research published last Julyfound that in 22% of emergency room cases from 2011 to 2015 — almost 1 in 4 — patients went to an in-network hospital but were treated by an out-of-network doctor.
The risks are more than just credit rating, Collins warned. Consumers delay education plans, or take out extra credit cards to pay off their bills. They may forestall other medical care, for fear of another unaffordable expense.
By comparison, Woodard got off easy. With the help of his parents, he eventually won the fight and his health plan paid the difference.
Woodard’s debt was settled just days before it was set to hit his credit report. He has since been able to purchase a new car — replacing an older one — with favorable terms that would have been unavailable to him had this situation turned out differently.
His 72-year-old father, Chuck Woodard, is now advocating for changes in how Colorado bills patients.
“No one tells you what your rights are,” Chuck Woodard said. “The only reason this consumer, Jeff, knew what was going on … was he had two retired parents who got pissed off.”
But Jeff Woodard’s case may not be over yet. This March, he received another bill for an ambulance he took to the hospital.
He has started negotiating once more, with his insurance plan and the fire department’s billing company. And based on his experience, he doesn’t expect an easy process.
“I was incredibly well-advantaged, and I barely made it through,” he said.

Chemo-Induced Neuropathy Common after Childhood Cancer

Chemotherapy-induced peripheral neuropathy is common in childhood cancer survivors and should be screened for in follow-up clinics, a cross-sectional analysis from Australia suggests.
Clinical abnormalities consistent with peripheral neuropathy occurred in about half of childhood cancer survivors 8.5 years after chemotherapy ended, with cisplatin producing long-term neurotoxicity more frequently than vinca alkaloids, reported Susanna Park, PhD, of the University of Sydney, and co-authors in JAMA Neurology.
“Traditionally, chemotherapy-induced peripheral neuropathy in children has been thought of as something that may occur during treatment but largely resolves in the long term. This study suggests that this is not the case,” the study’s first author, Tejaswi Kandula, MBBS, of the University of New South Wales in Sydney, told MedPage Today.
“Given that childhood cancers are on the rise, with an incidence of approximately 17 children per 100,000, this study is important because it shines a light on what could be an often-overlooked late effect of childhood cancer treatment,” added Jonas Sokolof, DO, of New York University Langone’s Rusk Rehabilitation, who was not involved with the research.
“We know that about 60% of all childhood cancer survivors will develop late effects,” Sokolof told MedPage Today. While most of the emphasis has been on cardiac sequelaeinfertility, and secondary cancers, “peripheral neuropathy, like many other late effects of childhood cancer treatment, has the potential to be very debilitating.”
Neuropathy has been linked to common chemotherapy agents, including vincristine and other vinca alkaloids, cisplatin, and carboplatin. For this study, Kandula and colleagues recruited childhood cancer survivors who had been treated with chemotherapy before age 17 at Sydney Children’s Hospital. They excluded patients with other causes of neuropathy including diabetes, critical illness neuropathy or inherited neuropathic conditions, and other neurodevelopmental disorders.
Of 121 childhood cancer survivors in the study, 53.7% were male. Participants underwent neurotoxicity assessments at a median age of 16 — which was a median of 8.5 years after they completed treatment — with results compared to healthy age-matched controls. Among cancer survivors, vinca alkaloids and platinum compounds were the main neurotoxic agents used.
Clinical abnormalities in Total Neuropathy Scores were present in 50.5% of childhood cancer survivors who were treated with neurotoxic chemotherapy. Lower limb sural sensory amplitudes were smaller in cancer survivors who were exposed to neurotoxic chemotherapy compared with controls (mean reduction of 5.8 μV; 95% CI 2.8-8.8; P<0.001), suggesting a reduced number of functioning axons. Patient-reported outcomes showed lower quality of life and physical functioning scores tied to Total Neuropathy Scores.
Overall, abnormalities were more prevalent in patients who had been exposed to cisplatin. Given the limited literature about cisplatin toxicity in pediatric patients, the discrepancy between vincristine and cisplatin toxicity found in this study makes cisplatin-treated patients an important population to follow, Kandula observed.
The researchers’ finding that “half of childhood cancer survivors had clinically apparent chemotherapy-induced peripheral neuropathy is very similar to our recent report in adult women cancer survivors and should awaken clinical practice to address this neurotoxic side effect of cancer treatment,” Kerri Winters-Stone, PhD, of Oregon Health and Science University in Portland, who was also not involved with the study, told MedPage Today.
Neuropathy’s link to poorer quality-of-life scores in this analysis also is “distressing for young survivors because they have decades of education, work, and social plans ahead of them,” Winters-Stone added.
Childhood cancer survivors are at high risk of cardiovascular disease and diabetes which may affect peripheral nerves later in life, Kandula noted, and “chemotherapy-induced peripheral neuropathy means these patients have a reduced axonal reserve and are potentially more at risk of early peripheral neuropathy when risk factors are compounded.” Untreated neuropathy may hinder physical activity and compound future problems, but identifying neuropathy and prescribing physical therapy could help patients move and exercise more. The Total Neuropathy Score is “easily administered in less than 5 minutes and would make a good screening tool,” Kandula suggested.
While this analysis “confirms the assumption that peripheral neuropathy frequently persists in many childhood cancer survivors,” it provides only a snapshot of what these patients experience and does not reveal anything about cause and effect, Sokolof added.
The study was funded by grants from the National Health and Medical Research Council, the Cancer Institute of New South Wales, and funds from the Royal Australasian College of Physicians and Brain Sciences UNSW of the University of New South Wales, Sydney.
The researchers reported having no conflicts of interest.

Coherus target hiked by Maxim

Coherus Biosciences price target raised to $22 from $18 at Maxim. Maxim analyst Jason McCarthy raised his price target on Coherus Biosciences to $22 from $18 after the company announced that the FDA has accepted for review the recently re-submitted BLA for CHS-1701, a biosimilar version of Neulasta. The BSUFA date for a decision is November 3, he noted. The analyst keeps his Buy rating on Coherus Biosciences shares

Galectin Proceeds to Phase 3 for NASH Cirrhosis Med After FDA Meeting


 Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis, incorporating advice and guidance obtained in a meeting with the US Food and Drug Administration (FDA).
The target population of the Phase 3 clinical trial will be patients with NASH cirrhosis without esophageal varices. The primary endpoint will be chosen from two endpoints that the FDA agreed may be acceptable: The change in hepatic venous pressure gradient (HVPG), which is a measure of liver blood pressure, or the progression to esophageal varices. Both primary endpoints may be considered surrogate endpoints for clinical outcomes in the target population with NASH cirrhosis. Details of the Phase 3 clinical trial design, including projected timings and costs, will be announced once the planning phase has been completed and the company has a final clinical trial protocol that is acceptable to the FDA.
“Planning for a Phase 3 development program represents a significant milestone for Galectin Therapeutics and a pathway forward for the development of GR-MD-02 as a potentially important therapy in patients with NASH cirrhosis,” said Dr. Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics. The basis for advancing to Phase 3 is the positive effects of GR-MD-02 on HVPG and the possible prevention or postponement of development of esophageal varices in the Phase 2 NASH-CX trial, which we believe is the first large, randomized clinical trial of any drug to demonstrate a clinically meaningful improvement in these patients. The potential choice between two primary endpoints for Phase 3 trials provides enhanced flexibility in designing the strongest trial to replicate the efficacy demonstrated in the Phase 2 NASH-CX trial. Additionally, the clinical trial design discussed with the FDA provides for interim analysis which may provide confirmation of Phase 2 results and enhanced confidence for the ultimate results of the Phase 3 trial.
“While the company believes the results of the Phase 2 NASH-CX trial may represent a breakthrough for patients with NASH cirrhosis and believes that the results meet the FDA requirements for Breakthrough Therapy designation, the FDA has not granted breakthrough designation at this time based on the Agency’s current assessment that additional confirmatory data are needed to identify the level of change in HVPG that is reasonably likely to predict clinical outcomes. Although we disagree with FDA’s decision not to grant Breakthrough Therapy designation at this time, we understand their position because our NASH-CX trial is to our knowledge indeed the first randomized clinical trial of any drug to demonstrate a clinically meaningful improvement in HVPG in NASH cirrhosis patients. Importantly, the Phase 3 program will not be impeded by the lack of Breakthrough Designation at this time. The program continues to benefit from Fast Track designation which provides many of the same advantages as Breakthrough Therapy designation, including potential for accelerated approval and priority review.”

CVS on $40M Fred’s deal

CVS Health will grow its specialty pharmacy sector thanks to a $40 million deal with Fred’s.
Last week, Memphis-based general merchandise and pharmacy chain, Fred’s Inc., announced that it had entered into a definitive agreement to sell certain assets of its specialty pharmacy business — EntrustRx — to a subsidiary of CVS Health Corp. That $40 million deal is now awaiting regulatory approval.
Following that May 7 announcement, the Memphis Business Journal reached out to CVS for comment.
May 10, a CVS Health representative provided the following statement:
“CVS Health is committed to providing expert pharmacy care to our patients. With the upcoming acquisition of Entrust Rx, we will be able to introduce even more patients to our expert specialty pharmacy care. Our CVS Specialty Care Teams are specialists in medications that treat complex conditions and are committed to not only getting patients the medications they need, but also providing personalized clinical support. We are excited to bring our innovative specialty pharmacy care programs and services to Entrust Rx’s patients when the transaction is completed.”
This move is the latest action in Fred’s ongoing turnaround strategy.

Attacking the common cold by unshielding its genome

The problem with the common cold is that it isn’t just one virus. It’s a family of viruses that evolve so quickly no one can ever be fully immune to the cold, and developing a vaccine that can tackle all of the variations of the virus is impossible. But what if there were one way to block the ability of all cold viruses from replicating—thereby fending off the sneezing, sore throat and general misery that they cause?
Researchers at Imperial College London believe they’ve found a molecule that can block multiple strains of the cold by targeting a protein the virus needs to survive. They reported the discovery in the journal Nature Chemistry.
The molecule the researchers created, IMP-1088, homes in on a protein in cells called N-myristoyltransferase (NMT). When viruses invade the body, they use NMT to construct a shell that protects their genomes, which in turn allows them to make copies of themselves. Inhibiting NMT with IMP-1088 prevented multiple strains of the cold virus from “hijacking” human cells in lab tests, the researchers reported.
The Imperial College team came up with the idea for IMP-1088 when they were looking for a way to target NMT in malaria parasites. They found two compounds that seemed to work well together, so they combined them to make IMP-1088. The team was led by Andy Bell, who’s best known for creating Viagra while working in the research group at Pfizer.

Much of the effort to cure the common cold is centered around targeting the genomes of the viruses that cause it. Last year, a group of European scientists announced they had found a way to decode encrypted signals in the genome of human Parechovirus, which is part of the family of viruses that cause the common cold. The signals govern the assembly of the virus. With their newfound insight, they are working on identifying antiviral drugs that disrupt those signals.
The Imperial College researchers reported that IMP-1088 blocked the common cold without affecting healthy cells. They are now planning to move IMP-1088 into animal trials to ensure that it is safe and that it doesn’t target other conditions with different causes, according to the statement. They are also developing a way to deliver the drug via the lungs.
“The common cold is an inconvenience for most of us, but can cause serious complications in people with conditions like asthma and COPD,” said lead researcher Ed Tate, a professor of chemistry at Imperial College, in the statement. “A drug like this could be extremely beneficial if given early in infection, and we are working on making a version that could be inhaled, so that it gets to the lungs quickly.”